CYTOKINETICS, INCORPORATED Capital Expenditures Incurred but Not yet Paid
CYTOKINETICS, INCORPORATED (CYTK) reported Capital Expenditures Incurred but Not yet Paid of $113.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$4.07M, a 404.87% decline year-over-year.
- CYTOKINETICS, INCORPORATED capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $4.19M, a 180.19% increase year-over-year.
- CYTOKINETICS, INCORPORATED capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $562.00K, a 80.51% decline year-over-year.
- CYTOKINETICS, INCORPORATED capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$742.00K, a 288.32% decline year-over-year.
- CYTOKINETICS, INCORPORATED capital expenditures incurred but not yet paid for fiscal 2025 was $2.65M, a 20.78% decline from fiscal 2024.
- CYTOKINETICS, INCORPORATED capital expenditures incurred but not yet paid for fiscal 2024 was $3.35M.
- CYTOKINETICS, INCORPORATED capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- CYTOKINETICS, INCORPORATED capital expenditures incurred but not yet paid for fiscal 2022 was $621.00K, a 94.82% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $113.00K 10-Q · filed 2026-08-06 | $675.00K derived: sum of 3 quarters · filed 2026-08-06 | -$67.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.19M 10-Q · filed 2026-05-05 | $4.75M derived: sum of 2 quarters · filed 2026-05-05 | $4.01M derived: sum of 3 quarters · filed 2026-05-05 | $5.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$180.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.16M derived: sum of 3 quarters · filed 2026-08-06 | $2.65M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$742.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $594.00K derived: sum of 2 quarters · filed 2026-08-06 | $2.09M 10-Q · filed 2025-11-05 | $4.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.83M 10-Q · filed 2026-08-06 | $5.71M derived: sum of 3 quarters · filed 2026-08-06 | $6.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.49M 10-Q · filed 2026-05-05 | $4.38M derived: sum of 2 quarters · filed 2026-05-05 | $4.77M derived: sum of 3 quarters · filed 2026-05-05 | $3.08M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.28M derived: sum of 2 quarters · filed 2026-02-26 | $1.59M derived: sum of 3 quarters · filed 2026-02-26 | $3.35M 10-K · filed 2026-02-26 |
| 2024-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.29M derived: sum of 2 quarters · filed 2025-11-05 | $462.00K 10-Q · filed 2025-11-05 | $462.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $68.00K 10-Q · filed 2025-08-07 | $68.00K derived: sum of 3 quarters · filed 2026-02-26 | $68.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.75M 10-Q · filed 2025-05-06 | $1.75M derived: sum of 2 quarters · filed 2026-02-26 | $1.75M derived: sum of 3 quarters · filed 2026-02-26 | $1.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$473.00K derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$473.00K derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | -$1.25M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$473.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | -$1.25M derived: sum of 3 quarters · filed 2025-02-27 | -$4.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $473.00K 10-Q · filed 2024-05-10 | -$772.00K derived: sum of 2 quarters · filed 2025-02-27 | -$3.83M derived: sum of 3 quarters · filed 2025-02-27 | -$735.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.30M derived: sum of 2 quarters · filed 2025-02-27 | -$1.21M derived: sum of 3 quarters · filed 2025-02-27 | $621.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | -$3.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $37.00K derived: sum of 2 quarters · filed 2023-11-03 | $1.87M 10-Q · filed 2023-11-03 | $2.87M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $3.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.92M 10-Q · filed 2023-08-03 | $5.93M derived: sum of 3 quarters · filed 2024-02-28 | $7.64M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $1.83M 10-Q · filed 2023-05-05 | $2.84M derived: sum of 2 quarters · filed 2024-02-28 | $4.55M derived: sum of 3 quarters · filed 2024-02-28 | $10.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $2.72M derived: sum of 2 quarters · filed 2024-02-28 | $8.22M derived: sum of 3 quarters · filed 2024-02-28 | $11.98M 10-K · filed 2024-02-28 |
| 2021-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $7.21M derived: sum of 2 quarters · filed 2022-11-04 | $10.97M 10-Q · filed 2022-11-04 | $10.97M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $5.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $9.26M 10-Q · filed 2022-08-05 | $9.26M derived: sum of 3 quarters · filed 2023-03-01 | $9.26M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $3.76M 10-Q · filed 2022-05-06 | $3.76M derived: sum of 2 quarters · filed 2023-03-01 | $3.76M derived: sum of 3 quarters · filed 2023-03-01 | $3.76M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 derived: sum of 2 quarters · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $0.00 10-Q · filed 2021-08-06 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |